Ibrutinib for Chronic Lymphocytic Leukemia with <i>TP53</i> Alterations
Inhye E. Ahn, Xin Tian, Adrian Wiestner
Abstract
Ibrutinib in CLL with TP53 Alterations Patients with chronic lymphocytic leukemia with chromosome 17 abnormalities have a worse prognosis than those without such alterations. In this phase 2 study,...
Topics & Concepts
IbrutinibChronic lymphocytic leukemiaBruton's tyrosine kinaseMedicineLeukemiaInternal medicineCancer researchOncologyReceptorTyrosine kinaseChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentImmunodeficiency and Autoimmune Disorders